Predicting Outcomes in Prostate Cancer: How Many More Nomograms Do We Need?
Robert W. Ross, Philip W. Kantoff Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Decades from now, when we fully understand the biologic basis for the clinical heterogeneity of prostate cancer, we will think of the current era as the Golden Age of Prostate Nomograms. Driven by the paucity of randomized data to guide treatment decisions, particularly in localized disease, nomograms have proliferated. Currently, there are more than 40 published prostate cancer nomograms to help with multiple decisions, from the risk of prostate cancer to survival after the development of metastatic, castration-independent disease.1 We eagerly await the publication of a nomogram of nomograms that would be able to predict all prostate cancer outcomes from a few pieces of clinical data and the point totals from all the current nomograms. To this expanding literature, two new prostate cancer nomograms are added: Walz an
